Upperton, in collaboration with Medicon Valley Alliance, is pleased to invite you to an inspiring Boost Seminar.
This event is focused on the critical challenges of advancing complex molecules to early clinical development, particularly within the constraints of Annex 1 compliance.
The session combines introductions, networking, and a facilitated seminar to explore key issues such as securing small-scale aseptic capacity, managing accelerated clinical submission timelines, and overcoming formulation hurdles related to solubility and bioavailability.
Upperton’s 16-week sterile manufacturing roadmap will highlight how you can move from formulation to clinical submission sooner and with greater confidence. The discussion will extend to practical strategies for navigating CDMO selection and applying enabling technologies like spray drying for high-concentration biologics, providing a realistic path to faster clinical progress.
Key reasons to attend:
• De risk early clinical timelines
• Learn how to achieve faster clinical readiness
• Navigate EU GMP Annex 1 with confidence
• Make better early formulation and process decisions
• Get real world insight from peers and experts
Date: Tuesday, 23 June 2026
Time: 9:30 – 14:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Hub 2
Program
| 9:30 | Networking, registration and light breakfast |
| 10:00 | Welcome and introduction to Medicon Valley Alliance David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance |
| 10:10 | Sterile Manufacturing and the speed to early phase clinical submissions Ian Lafferty, Chief Technical Officer, Upperton |
| 11:00 | Q&A |
| 11:45 | Light Lunch/refresments & Mingle |
| 12:45 | Formulation and Delivery of Complex Molecules Through Spray Drying Richard Johnson, Chief Scientific Officer, Upperton |
| 13:30 | Q&A |
| 14:00 | End of Boost Seminar |
Speakers
 |
Ian Lafferty, Chief Technical Officer, Upperton
Ian has 30 years’ experience in early phase pharmaceutical development, spanning formulation design, process optimisation, and manufacture of diverse dosage forms, including high potency and complex molecules. He has held senior executive roles at multiple CDMOs, providing strategic and operational leadership to deliver high quality pharmaceutical services. |
 |
Richard Johnson, Chief Scientific Officer, Upperton
Dr Richard Johnson founded Upperton Pharma Solutions in 1999 and remains central to its strategic leadership. With over 30 years’ experience across pharmaceuticals, biotechnology, and drug delivery, including specialist expertise in pharmaceutical spray drying, he holds an honours degree in Biology from the University of York and a PhD from the University of Warwick, with a strong track record of advancing innovative medicines from early feasibility through to commercialisation.
|
| Organized by | In collaboration with |
 |
 |